Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis

References

• Agnelli, G., Becattini, C., Meyer, G., Munoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., Sueiro, M. R., Lambert, C., Gussoni, G., Campanini, M., Fontanella, A., Vescovo, G., Verso, M., & Caravaggio, I. (2020). Apixaban for the treatment of venous thromboembolism associated with cancer. New England Journal of Medicine, 382(17), 1599–1607. https://doi.org/10.1056/NEJMoa1915103
   PubMed Web of Science ®Google Scholar
• Al Mukdad, M., Al-Badriyeh, D., & Elewa, H. F. (2019). Cost-effectiveness evaluations among the direct oral anticoagulants for the prevention and treatment of venous thromboembolism: Systematic review. Clinical and Applied Thrombosis/Hemostasis, 25, 107602961984910. https://doi.org/10.1177/1076029619849103
   Web of Science ®Google Scholar
• Bertoletti, L., Madridano, O., Jimenez, D., Muriel, A., Bikdeli, B., Ay, C., Trujillo-Santos, J., Bosevski, M., Siguenza, P., & Monreal, M. (2023). Cancer-associated thrombosis: Trends in clinical features, treatment, and outcomes from 2001 to 2020. JACC: CardioOncology, 5(6), 758–772. https://doi.org/10.1016/j.jaccao.2023.09.003
   PubMedGoogle Scholar
• Chen, D. Y., Tseng, C. N., Hsieh, M. J., Lan, W. C., Chuang, C. K., Pang, S. T., Chen, S. W., Chen, T. H., Chang, S. H., Hsieh, I. C., Chu, P. H., Wen, M. S., Chen, J. S., Chang, J. W., See, L. C., & Huang, W. K. (2021). Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism. JAMA Network Open, 4(2), e2036304. https://doi.org/10.1001/jamanetworkopen.2020.36304
   PubMed Web of Science ®Google Scholar
• Chiang, C. L., Chan, S. K., Lee, S. F., & Choi, H. C. (2021). First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis. Cancers, 13(5), 931. https://doi.org/10.3390/cancers13050931
   PubMed Web of Science ®Google Scholar
• Chiang, C. E., Wang, K. L., & Lip, G. Y. (2014). Stroke prevention in atrial fibrillation: An Asian perspective. Thrombosis and Haemostasis, 112(5), 789–797. https://doi.org/10.1160/TH13-11-0948
   PubMedGoogle Scholar
• de Jong, L. A., van der Velden, A. W. G., Hulst, M. V., & Postma, M. J. (2020). Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism. BMJ Open, 10(11), e039057. https://doi.org/10.1136/bmjopen-2020-039057
   PubMed Web of Science ®Google Scholar
• Di Nisio, M., van Es, N., Carrier, M., Wang, T. F., Garcia, D., Segers, A., Weitz, J., Buller, H., & Raskob, G. (2019). Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. Journal of Thrombosis and Haemostasis, 17(11), 1866–1874. https://doi.org/10.1111/jth.14561
   PubMed Web of Science ®Google Scholar
• Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., Antic, D., Casais, P., Guillermo Esposito, M. C., Ikezoe, T., Abutalib, S. A., Meillon-García, L. A., Bounameaux, H., Pabinger, I., Douketis, J., … Yasuda, C. (2022). 2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. The Lancet Oncology, 23(7), e334–e347. https://doi.org/10.1016/S1470-2045(22)00160-7
   PubMed Web of Science ®Google Scholar
• Gidwani, R., & Russell, L. B. (2020). Estimating transition probabilities from published evidence: A tutorial for decision modelers. Pharmacoeconomics, 38(11), 1153–1164. https://doi.org/10.1007/s40273-020-00937-z
   PubMed Web of Science ®Google Scholar
• Gulati, S., & Eckman, M. H. (2023). Anticoagulant therapy for cancer-associated thrombosis: A cost-effectiveness analysis. Annals of Internal Medicine, 176(1), 1–9. https://doi.org/10.7326/M22-1258
   PubMed Web of Science ®Google Scholar
• Hogg, K., Kimpton, M., Carrier, M., Coyle, D., Forgie, M., & Wells, P. (2013). Estimating quality of life in acute venous thrombosis. JAMA Internal Medicine, 173(12), 1067–1072. https://doi.org/10.1001/jamainternmed.2013.563
   PubMed Web of Science ®Google Scholar
• Hong Kong Hospital Authority. (2023, October 31). Overview of Hong Kong cancer statistics. Retrieved October 31, 2024, from https://www3.ha.org.hk/cancereg/pub.html
   Google Scholar
• Hong Kong Monetary Authority. (2023, December 8). Monthly statistical bulletin. Retrieved December 8, 2024, from https://www.hkma.gov.hk/eng/data-publications-and-research/data-and-statistics/monthly-statistical-bulletin/table/
   Google Scholar
• Hong Kong Special Administrative Region Government. (2024, February 28). The 2024–25 budget. Retrieved February 28, 2024, from https://www.budget.gov.hk/2024/eng/speech.html
   Google Scholar
• The Hong Kong Trade Development Council (HKTDC). (2023, November 30). Economic and trade information on Hong Kong. Retrieved November 30, 2024, from https://research.hktdc.com/en/article/MzIwNjkzNTY5
   Google Scholar
• Hospital Authority. (2023, January 10). Fees and charges. Retrieved June 18, 2024, from https://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10045&Lang=ENG
   Google Scholar
• Hull, R. D., & Lip, G. Y. (2023, June 7). Venous thromboembolism: Anticoagulation after initial management. Retrieved June 7, 2024, from https://www-uptodate-com.eproxy.lib.hku.hk/contents/venous-thromboembolism-anticoagulation-after-initial-management?search=apixaban&source=search_result&selectedTitle=4~150&usage_type=default&display_rank=2
   Google Scholar
• Husereau, D., Drummond, M., Augustovski, F., de Bekker-Grob, E., Briggs, A. H., Carswell, C., Caulley, L., Chaiyakunapruk, N., Greenberg, D., Loder, E., Mauskopf, J., Mullins, C. D., Petrou, S., Pwu, R. F., Staniszewska, S., & Force, C. I. G. R. P. T. (2022). Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Value in Health, 25(1), 3–9. https://doi.org/10.1016/j.jval.2021.11.1351
   PubMed Web of Science ®Google Scholar
• Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., Gates, L. E., Kakkar, A. K., Levine, M. N., Liebman, H. A., Tempero, M. A., Lyman, G. H., & Falanga, A. (2020). Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. Journal of Clinical Oncology, 38(5), 496–520. https://doi.org/10.1200/JCO.19.01461
   PubMed Web of Science ®Google Scholar
• Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis, 5(3), 632–634. https://doi.org/10.1111/j.1538-7836.2007.02374.x
   PubMed Web of Science ®Google Scholar
• Khorana, A. A., Noble, S., Lee, A. Y. Y., Soff, G., Meyer, G., O'Connell, C., & Carrier, M. (2018). Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 16(9), 1891–1894. https://doi.org/10.1111/jth.14219
   PubMed Web of Science ®Google Scholar
• Kim, S. M., Jeon, E. T., Jung, J. M., & Lee, J. S. (2021). Real-world oral anticoagulants for Asian patients with non-valvular atrial fibrillation: A PRISMA-compliant article. Medicine, 100(32), e26883. https://doi.org/10.1097/MD.0000000000026883
   PubMed Web of Science ®Google Scholar
• Kimpton, M., Kumar, S., Wells, P. S., Coyle, D., Carrier, M., & Thavorn, K. (2021). Cost-utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer. Canadian Medical Association Journal, 193(40), E1551–E1560. https://doi.org/10.1503/cmaj.210523
   Web of Science ®Google Scholar
• Leung, L. L. (2023 July 27). Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects. Retrieved July 27, 2024, from https://www-uptodate-com.eproxy.lib.hku.hk/contents/direct-oral-anticoagulants-doacs-and-parenteral-direct-acting-anticoagulants-dosing-and-adverse-effects?search=apixaban&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=1#H10489655
   Google Scholar
• Li, A., Manohar, P. M., Garcia, D. A., Lyman, G. H., & Steuten, L. M. (2019). Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thrombosis Research, 180, 37–42. https://doi.org/10.1016/j.thromres.2019.05.012
   PubMed Web of Science ®Google Scholar
• Lip, G. Y., & Hull, R. D. (2023 March 15). Venous thromboembolism: Initiation of anticoagulation. Retrieved March 15, 2024, from https://www-uptodate-com.eproxy.lib.hku.hk/contents/venous-thromboembolism-initiation-of-anticoagulation?sectionName=Low%20molecular%20weight%20heparin&search=apixaban&topicRef=95395&anchor=H796357734&source=see_link#H105734355
   Google Scholar
• Lloyd, A. J., Dewilde, S., Noble, S., Reimer, E., & Lee, A. Y. Y. (2018). What Impact does venous thromboembolism and bleeding have on cancer patients’ quality of life? Value in Health, 21(4), 449–455. https://doi.org/10.1016/j.jval.2017.09.015
   PubMed Web of Science ®Google Scholar
• Lopes, D. G., Tamayo, A., Schipp, B., & Siepmann, T. (2020). Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil. Thrombosis Research, 196, 4–10. https://doi.org/10.1016/j.thromres.2020.08.014
   PubMed Web of Science ®Google Scholar
• Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., Noble, S., Sexton, E. A., Stenehjem, D., Wiercioch, W., Kahale, L. A., & Alonso-Coello, P. (2021). American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Advances, 5(4), 927–974. https://doi.org/10.1182/bloodadvances.2020003442
   PubMed Web of Science ®Google Scholar
• McBane, R. D., II, Wysokinski, W. E., Le-Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., Perez Botero, J., Leon Ferre, R. A., Henkin, S., Lenz, C. J., Houghton, D. E., Vishnu, P., & Loprinzi, C. L. (2020). Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. Journal of Thrombosis and Haemostasis, 18(2), 411–421. https://doi.org/10.1111/jth.14662
   PubMed Web of Science ®Google Scholar
• McShane, M., Senchak, J., Stack, A., Frimpong, J., Hellerslia, V., & Zhao, H. Q. (2020). A retrospective single-center evaluation of the safety and efficacy of direct oral anticoagulants versus low molecular weight heparin in patients with cancer-associated thrombosis. Journal of Clinical Oncology, 38(15), e24102. https://doi.org/10.1200/JCO.2020.38.15_suppl.e24102
   Web of Science ®Google Scholar
• Mulder, F. I., Horvath-Puho, E., van Es, N., van Laarhoven, H. W. M., Pedersen, L., Moik, F., Ay, C., Buller, H. R., & Sorensen, H. T. (2021). Venous thromboembolism in cancer patients: A population-based cohort study. Blood, 137(14), 1959–1969. https://doi.org/10.1182/blood.2020007338
   PubMed Web of Science ®Google Scholar
• Munoz, A., Gallardo, E., Agnelli, G., Crespo, C., Forghani, M., Arumi, D., Fernandez de Cabo, S., & Soto, J. (2022). Cost-effectiveness of direct oral anticoagulants compared to low-molecular-weight-heparins for treatment of cancer associated venous thromboembolism in Spain. Journal of Medical Economics, 25(1), 840–847. https://doi.org/10.1080/13696998.2022.2087998
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. (2015, June 4). Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. Retrieved from https://www.nice.org.uk/guidance/ta341/resources/apixaban-for-the-treatment-and-secondary-prevention-of-deep-veinthrombosis-andor-pulmonary-embolism-pdf-82602602803141
   Google Scholar
• National Institute for Health and Care Excellence. (2022, January 31). NICE health technology evaluations: The manual. Retrieved January 31, 2024, from https://www.nice.org.uk/process/pmg36/resources/nice-health-technology-evaluations-the-manual-pdf-72286779244741
   Google Scholar
• The Pharmacy and Poisons Board of Hong Kong. (2024, April 19). Registered pharmaceutical products. Retrieved April 19, 2024, from https://www.drugoffice.gov.hk/eps/do/en/pharmaceutical_trade/reg_pharm_products/index.html
   Google Scholar
• Planquette, B., Bertoletti, L., Charles-Nelson, Chest, Laporte, S., Grange, C., Mahe, I., Pernod, G., Elias, A., Couturaud, F., Falvo, N., Sevestre, M. A., Ray, V., Burnod, A., Brebion, N., Roy, P. M., Timar-David, M., Aquilanti, S., Constans, J., Bura-Riviere, A., … Investigators, C. D. T. (2022). Rivaroxaban vs dalteparin in cancer-associated thromboembolism. Chest, 161(3), 781–790. https://doi.org/10.1016/j.chest.2021.09.037
   PubMed Web of Science ®Google Scholar
• Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., Meyer, G., Segers, A., Shi, M., Wang, T. F., Yeo, E., Zhang, G., Zwicker, J. I., Weitz, J. I., Buller, H. R., & Hokusai, V. T. E. C. I. (2018). Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine, 378(7), 615–624. https://doi.org/10.1056/NEJMoa1711948
   PubMed Web of Science ®Google Scholar
• Schaefer, J. K., Li, M., Wu, Z., Basu, T., Dorsch, M. P., Barnes, G. D., Carrier, M., Griggs, J. J., & Sood, S. L. (2021). Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs. Journal of Thrombosis and Haemostasis, 19(1), 212–220. https://doi.org/10.1111/jth.15153
   PubMed Web of Science ®Google Scholar
• Schrag, D., Uno, H., Rosovsky, R., Rutherford, C., Sanfilippo, K., Villano, J. L., Drescher, M., Jayaram, N., Holmes, C., Feldman, L., Zattra, O., Farrar-Muir, H., Cronin, C., Basch, E., Weiss, A., Connors, J. M., & Investigators, C. (2023). Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer. JAMA, 329(22), 1924–1933. https://doi.org/10.1001/jama.2023.7843
   PubMed Web of Science ®Google Scholar
• Shah, S., Rubin, N., & Khorana, A. A. (2018). Economic burden of venous thromboembolism in cancer patients—A comparative analysis between matched patients with cancer with and without a diagnosis of venous thromboembolism. Blood, 132(Supplement 1), 366. https://doi.org/10.1182/blood-2018-99-113581
   Web of Science ®Google Scholar
• Streiff, M. B., Milentijevic, D., McCrae, K., Yannicelli, D., Fortier, J., Nelson, W. W., Laliberte, F., Crivera, C., Lefebvre, P., Schein, J., & Khorana, A. A. (2018). Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. American Journal of Hematology, 93(5), 664–671. https://doi.org/10.1002/ajh.25059
   PubMed Web of Science ®Google Scholar
• van der Wall, S. J., Klok, F. A., den Exter, P. L., Barrios, D., Morillo, R., Cannegieter, S. C., Jimenez, D., & Huisman, M. V. (2017). Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: A prospective cohort study in daily clinical practice. Journal of Thrombosis and Haemostasis, 15(1), 74–79. https://doi.org/10.1111/jth.13563
   PubMed Web of Science ®Google Scholar
• The World Bank. (2024, March 28). Life expectancy at birth, total (years) – World. Retrieved March 28, 2024, from https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=1W
   Google Scholar
• Wumaier, K., Li, W., Chen, N., & Cui, J. (2021). Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis. Thrombosis Journal, 19(1), 68. https://doi.org/10.1186/s12959-021-00319-1
   PubMed Web of Science ®Google Scholar
• Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., MacCallum, P., Kakkar, A., Hobbs, F. D. R., Petrou, S., Dale, J., Poole, C. J., Maraveyas, A., & Levine, M. (2018). Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20), 2017–2023. https://doi.org/10.1200/JCO.2018.78.8034
   PubMed Web of Science ®Google Scholar